California’s Most Vulnerable Patients Are Being Threatened

Healthcare Providers Urge Senate to Oppose Budget Proposal Eliminating 340B Drug Discount Program for Medi-Cal Patients

In a press release dated March 22, 2018, the Center For Inherited Blood Disorders has reported that patients with Chronic and debilitating illnesses will suffer under Brown administration proposal to eliminate the 340B Discount Drug Program.

Diane J. Nugent, M.D., Regional Director of the Western States Regional Hemophilia Network and also the Founder and Medical Director of the Center for Inherited Blood Disorders, urged members of the Senate Budget Subcommittee on Health to oppose the Brown Administration’s 2018-19 budget proposal to eliminate the outpatient discount drug program for Medi-Cal beneficiaries, citing dire fiscal impacts to California’s eleven Hemophilia Treatment Centers (HTCs) serving more than 9,000 patients each year.

During 2014-2016, over 80 percent of the teams and services provided to HTC patients, at a cost in excess of $15 million per year, have been supported by income generated by 340B pharmacy services. Eliminating 340B funding would create a substantial shortfall and could result in the loss of patient services in all areas.

To read the full press release, CLICK HERE.

About the Author: